Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity
- 1 March 2007
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 37 (3), 758-767
- https://doi.org/10.1002/eji.200636593
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent mannerThe Journal of Experimental Medicine, 2005
- Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumorInternational Journal of Cancer, 2005
- Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 primingNature Immunology, 2004
- CD95L mediates tumor counterattack in vitro but induces neutrophil‐independent tumor rejection in vivoInternational Journal of Cancer, 2004
- Cancer Immunotherapy: A Treatment for the MassesScience, 2004
- Human CD4+CD25+ regulatory T cellsSeminars in Immunology, 2004
- The Dynamic Life of Natural Killer CellsAnnual Review of Immunology, 2004
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- Regulation of tumour immunity by CD25+ T cellsImmunology, 2002
- FAS Engagement Induces the Maturation of Dendritic Cells (Dcs), the Release of Interleukin (Il)-1β, and the Production of Interferon γ in the Absence of IL-12 during Dc–T Cell Cognate InteractionThe Journal of Experimental Medicine, 2000